How Come Mary-Jane is Not on Workers’ Comp?: Requiring Rhode Island Workers’ Compensation Insurers to Reimburse Employees for Medical Marijuana by Toro, Devon Q.
Roger Williams University Law Review 
Volume 25 
Issue 3 Vol. 25, No. 3 Summer 2020 Article 10 
Summer 2020 
How Come Mary-Jane is Not on Workers’ Comp?: Requiring 
Rhode Island Workers’ Compensation Insurers to Reimburse 
Employees for Medical Marijuana 
Devon Q. Toro 
Candidate for Juris Doctor, Roger Williams University School of Law 
Follow this and additional works at: https://docs.rwu.edu/rwu_LR 
 Part of the Food and Drug Law Commons, Health Law and Policy Commons, and the Workers' 
Compensation Law Commons 
Recommended Citation 
Toro, Devon Q. (2020) "How Come Mary-Jane is Not on Workers’ Comp?: Requiring Rhode Island Workers’ 
Compensation Insurers to Reimburse Employees for Medical Marijuana," Roger Williams University Law 
Review: Vol. 25 : Iss. 3 , Article 10. 
Available at: https://docs.rwu.edu/rwu_LR/vol25/iss3/10 
This Notes and Comments is brought to you for free and open access by the School of Law at DOCS@RWU. It has 
been accepted for inclusion in Roger Williams University Law Review by an authorized editor of DOCS@RWU. For 
more information, please contact mwu@rwu.edu. 
500 
How Come Mary-Jane is Not on 
Workers’ Comp?: Requiring Rhode 
Island Workers’ Compensation 
Insurers to Reimburse Employees for 
Medical Marijuana 
Devon Q. Toro* 
INTRODUCTION 
On May 20, 2019, Beacon Mutual1 (Beacon) sent a letter to 
Rhode Island Senator Erin Lynch Prata regarding a proposed 
amendment to include “acute pain” as one of the debilitating 
conditions2 for qualification under the Edward O. Hawkins and 
Thomas C. Slater Medical Marijuana Act, colloquially known 
simply as the Slater Act.3  The letter was sparked by a recent influx 
of employees across the country seeking medical marijuana, 
perhaps in light of the opioid crisis, as a means of remedying the 
* Candidate for Juris Doctor, Roger Williams University School of Law,
2021. I would like to thank my parents, Pam and John, and my sister, Quinn, 
for their endless love and support. I want to give a special nod to my father for 
inspiring the title of my Comment.  I also want to thank my faculty advisor, 
Professor Tanya Monestier, for her guidance and expertise during the writing 
process. 
1. Based in Rhode Island, the Beacon Mutual Insurance Company is
responsible for providing over 11,000 businesses in the state with workers’ 
compensation insurance.  See Letter from Michael D. Lynch, Beacon Mutual 
Ins. Co., to Senator Erin Lynch Prata, Chairperson, Senate Judiciary Comm., 
R.I. Senate (on file with author) (May 20, 2019).
2. 21 R.I. GEN. LAWS § 21-28.6-3(7) (laying out the “[d]ebilitating medical
conditions” a patient must have to receive medical marijuana in Rhode Island). 
3. § 21-28.6-1; Lynch, supra note 1.
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effects of work-related injuries; such employees will of course seek 
compensation for their out of pocket costs.4  In its letter, Beacon 
expressed opposition to the proposed amendment to include acute 
pain as a qualifying condition because it would open the door to a 
swarm of employee workers’ compensation claims seeking medical 
marijuana for pain management, given that a majority of 
employees on workers’ compensation have acute pain as a side 
effect of their injuries.5  Resting on arguments related to cost and 
the federal prohibition of marijuana as a controlled substance, 
Beacon urged the legislature either to forgo the addition of acute 
pain to the list of qualifying conditions or, in the event of inclusion, 
carve out an exception insulating Rhode Island workers’ 
compensation insurers from having to reimburse employees’ claims 
seeking medical marijuana in conjunction with their work-related 
injuries.6  Ultimately, the legislature declined to add acute pain to 
the list of qualifying conditions and incorporated an exception 
regarding workers’ compensation insurers, which states that 
insurers are not required to reimburse employees for the costs 
associated with the use of medical marijuana.7  
This Comment analyzes the arguments both for and against 
the carve out for workers’ compensation insurers in the Slater Act. 
Given public policy concerns surrounding the opioid crisis, the fact 
that medical marijuana is more cost-effective than other pain 
management medications, and the lack of a credible threat of 
federal prosecution, the Slater Act should be amended to 
affirmatively require Rhode Island workers’ compensation insurers 
to reimburse employees for the costs associated with medical 
marijuana.  So long as an employee is registered as a qualifying 
patient, her injury is work-related, and her doctor opines that 
medical marijuana is necessary to cure, relieve, or rehabilitate her 
4. See Mack Babcock, Workers’ Compensation and Medical Marijuana:
When Will We Bridge the Gap?, WORKERS’ INJURY L. & ADVOC. GROUP, (July 16, 
2019), https://www.wilg.org/?pg=WILGBlog&blAction=showEntry&blogEntry 
=8525 [https://perma.cc/4B5T-N4NJ].  
5. Lynch, supra note 1.
6. Id. (referring to 21 U.S.C. § 812).
7. An Act Relating to Making Appropriations in Support of FY 2020, 2019
Pub. L. R.I. ch. 88, art. 14 § 5 (amending 21 R.I. GEN. LAWS § 21-28.6-7(b)(1)).  
Compare S. 830, 2019 Gen. Assemb., Jan. Sess. (R.I. 2019) (seeking to add 
“acute pain” as a condition for which a person could be prescribed medical 
marijuana) with § 21-28.6-3 (lacking such amendment). 
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injury, the cost of medical marijuana qualifies for reimbursement 
under the Rhode Island Workers’ Compensation Act.8  Workers’ 
compensation insurers would be completely within the bounds of 
Rhode Island state law when reimbursing employees who have met 
the above criteria for medical marijuana.  Moreover, failure to 
reimburse such employees goes against the Rhode Island Workers’ 
Compensation Act as written.  There is nothing under Rhode Island 
state law prohibiting this type of reimbursement; rather, the 
legislature’s conscious decision to give workers’ compensation 
insurers the choice to reimburse infers that this conduct is 
consistent with state law.  As described later in this Comment, this 
conduct is also in conformity with federal law, thus debunking any 
opposing arguments of illegality.  
Part I of this Comment discusses Rhode Island’s Workers’ 
Compensation Act and includes an in-depth review of the statutory 
requirements an employee must meet to receive benefits and 
pertinent medical services.  Part II details Rhode Island’s legal 
status on medical marijuana, including the protections for its use 
and whether patients are entitled to reimbursement, and 
illuminates Beacon’s motive for opposing the amendment in the 
first place.  Part III analyzes various arguments for requiring 
Rhode Island workers’ compensation insurers to reimburse 
employees for the costs associated with medical marijuana.  This 
section explores both cost consideration in comparison with other 
pain medications and a public policy argument favoring medical 
marijuana over opioids. Part IV addresses various 
counterarguments rooted in the federal prohibition of marijuana 
and concludes that these arguments in fact lack merit.  Lastly, Part 
V challenges the current statute and recommends statutory reform 
to require workers’ compensation insurers to affirmatively 
reimburse employees for the costs of medical marijuana. 
I. THE RHODE ISLAND WORKERS’ COMPENSATION ACT
In order to qualify for workers’ compensation benefits in Rhode 
Island, an injured employee must meet several statutory 
requirements.9  The statute requires that the employee must be 
8. See § 21-28.6-3(25); 28 R.I. GEN. LAWS § 28-33-5.
9. See § 28-33-1.
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injured during the course of her employment.10  An employee must 
show that her injury is both work-related—sustained on the job—
and that she has an ongoing disability preventing her from 
performing her regular duties.11  If an employee’s injury is not 
work-related or she recovers enough to perform her regular duties, 
all weekly workers’ compensation benefits are discontinued, but 
medical benefits remain so long as the employee proves them 
necessary to cure, relieve, or rehabilitate the effect of her injury.12  
Furthermore, if the employee can prove a work-related injury and 
an ongoing disability, she also is entitled to several other benefits 
besides her weekly check, which only accounts for her lost earnings. 
These additional benefits include dependency benefits, benefits for 
scarring and loss of use, and most importantly, the reimbursement 
or pre-approval of medical services and prescriptions. 13 
Simply because employees are entitled to reimbursement for 
medications does not necessarily mean that workers’ compensation 
insurers automatically approve all requests.  In most cases, the 
employee must prove that the requested medication is both 
“reasonable” and “necessary . . . to cure, rehabilitate or relieve the 
employee from the effects of [her] injury.”14  Reasonableness is 
determined based on what is accepted by doctors on a national 
level.15  With regard to the “necessary” requirement, an employee 
must present a doctor’s recommendation that the treatment, 
10. Id. (referring to an employee who receive a “personal injury arising out
of and in the course of his or her employment, connected and referable to the 
employment”).  
11. See Tromba v. Harwood Mfg. Co., 177 A.2d 186, 188 (R.I. 1962) (holding
there must be “the establishment of a nexus between the injury and h[er] 
employment”); see also Maresca v. Lumber Mut. Cas. Ins. Co., 107 A.2d 343, 
344 (R.I. 1954) (explaining that expert testimony is used to establish extent of 
injury). 
12. Wright v. R.I. Super. Ct., 535 A.2d 318, 320 (R.I. 1988).
13. § 28-33-5 (providing for covered medical services); § 28-33-17(c)
(providing for dependency benefits); § 28-33-19 (providing compensation for 
permanent disfigurement and loss of use); see also Mendes v. ITT Royal Elec., 
647 A.2d 1358, 1360 (R.I. 1994) (holding that employees are entitled to seek 
determination from Workers’ Compensation Court regarding pre-
authorization of expenses for treatment to avoid situations where employees 
must choose to obtain medical services without knowing in advance if insurer 
will provide coverage). 
14. § 28-33-5.
15. Pola v. Health-Tex, Inc., 605 A.2d 1321, 1323 (R.I. 1992).
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medical device, service, or medication is necessary to cure, 
rehabilitate, or relieve her work-related injury.16  If an employee 
can show that the requested medication is both reasonable and 
necessary to cure, rehabilitate, or relieve her injury, the insurer 
must reimburse the employee for any associated expenses.  If the 
insurer does not voluntarily reimburse the employee, she can file a 
petition with the Rhode Island Workers’ Compensation Court, 
where the judge makes the determination.17  So long as the 
employee can prove both requirements, the judge will generally 
require the insurer to reimburse the employee for associated 
expenses; otherwise, the employee can file an appeal.18  Given that 
reimbursement of medical marijuana is a relatively new issue and 
judges are cognizant of the federal prohibition, there has been 
hesitancy on the part of insurance companies to reimbursee 
employees for the associated expenses.19  This Comment 
illuminates the intricacies of both the law governing medical 
marijuana and the federal prohibition in an attempt to quell any 
hesitation.  
II. THE SLATER ACT
Medical marijuana was legalized in Rhode Island in 2006 
under the Slater Act, based on the notion that it was beneficial in 
alleviating pain associated with various debilitating conditions 
including glaucoma, cancer, and other chronic conditions.20  
Although medical marijuana is legal in Rhode Island under the 
Slater Act, patients must satisfy several statutory requirements 
before they are approved for medical use.21  Medical marijuana is 
only available to those who are registered “cardholders,” meaning 
those who have been “registered or licensed with the department of 
health or the department of business regulation pursuant to [the 
16. See Geigy Chem. Corp. v. Zuckerman, 261 A.2d 844, 849 (R.I. 1970).
17. § 28-33-8(f)(1).
18. § 28-35-28(a).
19. See Babcock, supra note 4.
20. 21 R.I. GEN. LAWS § 21-28.6-1.  Cannabis was only legalized for medical
use; there have been several bills since proposing recreational legalization, 
none of which have passed.  See generally § 21-28.6-2; Felicia Gans, Plans for 
Legal Pot in R.I. Burn Out: Many Expected State to Decriminalize Recreational 
Marijuana, BOS. GLOBE, June 21, 2019, at B1. 
21. See § 21-28.6-4.
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Slater Act] and possess a valid registry identification card or 
license.”22  In order to register as a cardholder, a Rhode Island 
resident must be deemed a qualifying patient and be certified by a 
practitioner as having one of the debilitating medical conditions 
enumerated in the Slater Act.23 
Rhode Island has never required any type of insurer, whether 
it be private, state-subsidized, or workers’ compensation, to 
reimburse patients for the costs associated with medical 
marijuana.24  Prior to the 2019 amendment, the Slater Act carved 
out an exception providing that government medical assistance 
programs and private health insurers were not required to 
reimburse patients for the associated costs of medical marijuana, 
with no mention of workers’ compensation insurers.25  Accordingly, 
while the statute’s language left discretion to governmental and 
private insurers in deciding whether to reimburse patients, its 
silence with regard to workers’ compensation insurers resulted in 
uncertainty.26  After the amendment, the statute now affirmatively 
states that workers’ compensation insurers have discretion 
regarding reimbursement.27  The current statute reads as follows: 
“Nothing in this chapter shall be construed to require: . . . [a] 
government medical assistance program or private health insurer 
or workers’ compensation insurer, workers’ compensation group self-
22. § 21-28.6-3(4).
23. § 21-28.6-3(25).  The statute defines the term “debilitating medical
condition” as: 
(i) Cancer, glaucoma, positive status for human immunodeficiency
virus, acquired immune deficiency syndrome, Hepatitis C, post-
traumatic stress disorder, or the treatment of these conditions;
(ii) A chronic or debilitating disease or medical condition, or its
treatment, that produces one or more of the following: cachexia or
wasting syndrome; severe, debilitating, chronic pain; severe nausea;
seizures, including but not limited to, those characteristic of epilepsy;
or severe and persistent muscle spasms, including but not limited to,
those characteristic of multiple sclerosis or Crohn’s disease; or
agitation of Alzheimer’s Disease; or
(iii) Any other medical condition or its treatment approved by the
department of health, as provided for in § 21-28.6-5.
§ 21-28.6-3(7).
24. See § 21-28.6-7(b)(1).
25. See supra note 7.
26. See supra note 7.
27. § 21-28.6-7(b)(1).
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insurer, or employer self-insured for workers’ compensation 
under § 28-36-1 to reimburse a person for costs associated with the 
medical use of marijuana.”28 
III. RHODE ISLAND WORKERS’ COMPENSATION INSURERS SHOULD BE
REQUIRED TO REIMBURSE EMPLOYEES FOR COSTS ASSOCIATED WITH
MEDICAL MARIJUANA 
Rhode Island workers’ compensation insurers should be 
required to reimburse employees for the costs associated with 
medical marijuana to the extent necessary to relieve or rehabilitate 
an employee’s work-related injury because it is more cost effective 
than reimbursement of comparable pain management medications 
currently reimbursed.  Reimbursement also comports with public 
policy concerns in light of the opioid crisis because marijuana is less 
addictive than other pain-management medications.29  Further, 
any hesitancy with respect to the federal prohibition is unfounded 
because reimbursing employees for the costs of medical marijuana 
is not a violation of the Controlled Substances Act.30  Moreover, the 
federal government has expressed a disinterest in prosecuting 
medical marijuana related conduct that takes place within a 
comprehensive state regulatory scheme, such as Rhode Island’s 
medical marijuana program.31  Based on the above, Rhode Island 
workers’ compensation insurers should be required to reimburse 
injured employees for the associated costs of medically necessary 
medical marijuana treatment. 
28. Id. (emphasis added).
29. See Hal Arkowitz & Scott O. Lilienfeld, Experts Tell the Truth About
Pot: Marijuana Use Can Be Problematic but Only Rarely Leads to Addiction, 
SCI. AM.: MIND (Mar. 1, 2012), https://www. scientificamerican.com/ 
article/the-truth-about-pot/ [https://perma.cc/4HCG-U8YX]; see also supra 
Part I (discussing criteria of treatments for coverage by workers’ compensation 
insurers). 
30. See infra Part IV.
31. See § 21–28.6–2(2)–(4); see also James M. Cole, Deputy Attorney
Gen., Guidance Regarding Marijuana Enforcement, 26 FED. SENT’G REP. 217, 
219 (2014) (originally published Aug. 29, 2013). 
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A. Reimbursement of Medical Marijuana is More Cost-Effective
than Other Pain Medications Currently Reimbursed by Rhode
Island Workers’ Compensation Insurers.
Viewed in light of all surrounding circumstances, medical 
marijuana is more cost-effective than the average opioid 
prescription, making it a financially beneficial pain management 
substitute for insurers.  Pain management refers to techniques 
used to lessen someone’s pain.   Pain management plays a large role 
in curing, rehabilitating, and relieving employees from the effects 
of work-related injuries.  Techniques include physical therapy, 
medication, and surgical intervention.32  No matter the chosen 
route, employees partake in pain management practices to lessen 
the effects of their injuries with the goal that they will eventually 
return to work.  The pain management technique employed, 
however, depends upon the nature of the injury and the type of pain 
experienced.  Generally, pain is classified as either chronic or 
acute.33  Unlike chronic pain, which lasts more than six months and 
normally persists after an injury is fully healed, acute pain is short 
in duration and dissipates when the underlying cause has been 
cured.34  Prescription opioids and medical marijuana are two of the 
possible pain management methods available to patients for the 
treatment of chronic pain. 
The average annual opioid prescription costs anywhere from 
$2944 to $5840 depending on the patient’s daily dosage, which can 
range from two to four tablets daily.35  When it comes to opioids, 
costs of weaning must also be taken into account given the addictive 
 32. Pain Management: Non-Opioid Treatment, AM. SOC.
ANESTHESIOLOGISTS, https://www.asahq.org/whensecondscount/pain-manage 
ment/non-opioid-treatment/ [https://perma.cc/7GPU-L3DA] (last visited Apr. 
8, 2020). 




35. Oxycodone, CESAR (Oct. 29, 2013), http://www.cesar.umd.edu/
cesar/drugs/oxycodone.asp [https://perma.cc/3EB2-Q4GV] (“A 40mg tablet [of 
OxyContin] (prescribed from a doctor) costs approximately $4 . . . .  A typical 
dose prescribed by a physician ranges from two to four tablets daily.”).  This 
figure involves Oxycodone.  Oxycodone is only one of many opioid prescriptions 
available to patients, so this figure may vary depending on the actual 
medication prescribed. 
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nature of opioids and the fact that the excess cost of treatment for 
opioid use disorders can reach upwards of $5000 yearly.36  Weaning 
is not only expensive, but also taxing on the employee as it often 
includes methadone treatment and psychological services.37  
Untreated opioid use disorders are even more costly than 
weaning.38  For instance, the economic impact of untreated 
addiction is felt in the criminal justice system when judicial 
resources are expended in pursuit of rehabilitating addicts.39  It is 
also felt in the healthcare system, where addicted persons are 
treated for overdoses, and babies born dependent must be 
weaned.40  Most importantly here, it is felt by employers when 
previously injured employees return to the workforce less 
productive than before as a result of opioid use disorders.41  
Because medical marijuana mitigates the risk of opioid use 
disorders and may even help patients undergoing withdrawals from 
opioid addiction, there are fewer weaning expenses and economic 
impacts on society.42   
In Rhode Island, the average cost of medical marijuana is 
roughly between $255 and $308 per ounce.43  However, under the 
36. See Medications to Treat Opioids Use Disorder, NAT’L INST. ON DRUG
ABUSE, https://www.drugabuse.gov/publications/research-reports/medications 
-to-treat-opioid-addiction/how-much-does-opioid-treatment-cost [https://perma






42. See Beth Wiese & Adrianna, R. Wilson-Poe, Emerging Evidence for
Cannabis’ Role in Opioid Use Disorder, 3 CANNABIS & CANNABINOID RES. 179,
185 (2018).  About 9% of marijuana users become addicted to marijuana; this 
includes both users for medical and recreational use.  Nora D. Volkow et al., 
Adverse Health Effects of Marijuana Use, NEW ENG. J. MED., 2219, 2219 (2014).
About 8–12% of opioid users become addicted; of this group about 4-6% 
transition to heroin use.  Opioid Overdose Crisis, NAT’L INST. ON DRUG ABUSE 
(Feb. 2020), https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-
crisis [https://perma.cc/JS5M-G3P2].   
43. The Average Cost of Marijuana by State, OXFORD TREATMENT CTR. (Feb.
20, 2020), https://www.oxfordtreatment.com/substance-abuse/marijuana/ 
average-cost-of-marijuana/ [https://perma.cc/3ZZ4-KM8M].  Oxford’s charts 
indicate that prices in Rhode Island vary anywhere from $202 to $424.  Id.  
Marijuana is sold by the gram; however, price conversion is simple—one ounce 
is roughly 28 grams.  See Jeffery Stamberger, Marijuana Prices and Sizes, 
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Slater Act, a compassion center can only dispense 2.5 ounces to a 
patient within a fifteen-day period.44  With these dispensing limits, 
the most a workers’ compensation insurer would be required to 
reimburse an employee for a medical marijuana prescription is 
somewhere between $1275 and $1540 per month.45  However, this 
maximum number may not be not reflective of the actual cost a 
workers’ compensation insurer would have to pay per month.46  One 
study showed that the average individual dosage of marijuana for 
pain is one to two marijuana cigarettes per day, with each cigarette 
containing 0.5 grams of marijuana.47  Thus, an employee would use 
anywhere from fifteen to thirty grams of marijuana per month, 
which roughly translates to 0.5 to 1 ounce per month.48  Applying 
Rhode Island’s average cost per ounce, a workers’ compensation 
insurer would reimburse an average of $127 to $308 per month for 
an employee, yielding a yearly cost of $2613.49  Given these figures, 
the average medical marijuana prescription is significantly less 
expensive than an opioid prescription.  In a business where cash is 
king, any saved expense is beneficial for insurers, making medical 
marijuana a great option when compared with opioids.  The 
numbers speak for themselves—medical marijuana is a more cost-
effective pain medication and is ultimately less expensive for 
insurers when compared with opioids.  Because the cost of the 
average medical marijuana prescription is lower than that of 
opioids and there is no cost of weaning associated with marijuana 
MEDICAL MARIJUANA, INC. (Oct. 9, 2019), https://www.medical 
marijuanainc.com/marijuana-sizes-prices/ [https://perma.cc/5ATE-KFSZ]. 
44. 21 R.I. GEN. LAWS § 21–28.6–12(g)(1).
45. Calculated by multiplying the average price per ounce by two and a
half (2.5) (as that is the maximum prescription for a fifteen-day period) and 
then multiplying that by two (2), as there are two (2) fifteen-day periods within 
a month. 
46. See Kevin P. Hill, Medical Marijuana for Treatment of Chronic Pain
and Other Medical and Psychiatric Problems: A Clinical Review, 313 JAMA 
2474, 2481 (2015) (suggesting the amount of marijuana that a person would 
ingest daily would be a cheaper alternative to other, opioid-based solutions). 
47. Id.
48. See id.
49. This figure was calculated by multiplying the lowest average
prescription price (0.5 oz/$127.50) by twelve months and then multiplying the 
highest average prescription price (1 oz/$308) by twelve months and then 
averaging the two. 
510 ROGER WILLIAMS UNIVERSITY LAW REVIEW [Vol. 25:500 
use, any argument that the financial impact of reimbursement will 
overburden workers’ compensation insurers is without force.   
Insurers fear that by reimbursing medical marijuana, more 
injured employees will seek reimbursement and drive up the cost 
for insurers through a flood of claims.50  This argument is 
unsupported because the pool of individuals eligible for medical 
marijuana reimbursement associated with workers’ compensation 
injuries is so small that there will hardly be an uptick in employees 
seeking reimbursement; thus, the cost of reimbursement will be 
low.  Before reimbursement is even considered, the employee must 
first qualify under the Slater Act, meaning that she must establish 
one of the qualifying conditions and be certified by a practitioner.51  
Then, the injured employee must also fulfill the statutory 
requirements prescribed under the Rhode Island Workers’ 
Compensation Act.  She would have to prove a work-related injury, 
that she is disabled from her regular duties at work, and that 
medical marijuana is necessary to cure, relieve, or rehabilitate the 
effects of her work-related injury.52  Considering these parameters, 
the universe of employees who will seek reimbursement for the cost 
of medical marijuana would be lower than expected.53  As such, any 
fears of the compensation floodgates opening are unwarranted. 
Because the requirements for reimbursement would be 
considerable and take place under a heavily regulated system, the 
number of employees actually eligible would be relatively small and 
already included in the pool of employees receiving alternative pain 
management medications, such that workers’ compensation 
insurers’ costs would remain low. 
50. See Lynch, supra note 1; Mark Kraemer, How Do You Handle Medical




51. 21 R.I. GEN. LAWS § 21-28.6-3(7).
52. 28 R.I. GEN. LAWS § 28-33-5.
53. See R.I. DEP’T OF HEALTH, 2019 MEDICAL MARIJUANA PROGRAM REPORT
TO THE RHODE ISLAND GENERAL ASSEMBLY 1 (2019).  According to the Rhode 
Island Department of Health, there were 17,994 active registered patients 
participating in the state’s Medical Marijuana Program as of December 31, 
2019.  Id.  
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B. Requiring Rhode Island Workers’ Compensation Insurers to
Reimburse Employees for the Cost of Medical Marijuana Favors
Public Policy in Light of the Opioid Crisis.
Reimbursing the costs of medical marijuana in the context of 
workers’ compensation is favorable in light of the opioid crisis 
because it would reduce the number of injured employees on 
opioids, in turn reducing the number of employees who become 
addicted to opioids.  Prescribing medical marijuana in lieu of other 
pain management medications furthers the public agenda of 
combatting the opioid crisis.  Opioid abuse has run rampant in the 
United States for several years, claiming hundreds of thousands of 
victims.54  Since the early 2000s, close to 220,000 Americans have 
died as a result of opioid abuse, which has spawned a need for 
alternative methods in pain management practices.55  Opioid use 
disorder is especially prevalent in the realm of workers’ 
compensation, given that injured employees often are prescribed 
pain management medications in conjunction with their work-
related injuries.56  Many workers’ compensation insurers report 
that over fifty percent of claimants who have lost time out of work 
as a result of their injuries have been prescribed opioids, which 
indicates a drastic overprescribing rate in workers’ compensation.57  
In light of the opioid crisis, insurers, medical professionals, and 
patients have looked for other suitable pain-management options, 
including less-potent anti-inflammatory medications, costly 
physical therapy, and more invasive treatments like spinal cord 
injections.58  However, none of the above-mentioned options work 
as well as opioids.59  Thus there is a need for a better, safer 
alternative.  
54. James G. Hodge, Jr. et al., From Opioids to Marijuana: Out of the
Tunnel and into the Fog, 67 KAN. L. REV. 879, 882 (2019). 
55. See id.
56. See JOSEPH PADUDA, PRESCRIPTION DRUG MANAGEMENT IN WORKERS’
COMPENSATION: THE FIFTEENTH ANNUAL SURVEY REPORT 8 (2018), 
https://comppharma.com/wp-content/uploads/2018/07/2018-CompPharma-Rx-
Drug-Mng-Survey-Public.pdf [https://perma.cc/BU3L-3V5M].  
57. Id.
58. Hodge, supra note 54, at 889.
59. See id.
512 ROGER WILLIAMS UNIVERSITY LAW REVIEW [Vol. 25:500 
Marijuana is proven to be an effective treatment for various 
chronic pain conditions.60  There have been several clinical studies 
analyzing the efficacy of medical marijuana in treating pain, most 
of which have found it to be beneficial.61  An article evaluating 
various scientific studies regarding the efficacy of medical 
marijuana in relieving pain established that all studies examined 
found significant pain relief.62  Moreover, scientific studies have 
found that marijuana may actually be superior to opioids in 
alleviating pain symptoms.63  States which have legalized medical 
marijuana saw a drop in opioid-related prescriptions, indicating 
that patients previously prescribed opioids found medical 
marijuana to be a suitable substitute.64  Aside from its effectiveness 
as a pain-reliver, marijuana has also been beneficial in treating 
opioid use disorder during the weaning process.65  Not only is 
medical marijuana an adequate pain management substitute for 
injured employees, it is also a potential tool to combat the opioid 
crisis.66   
Resistance from insurers to routine medical marijuana use for 
pain-management purposes stems in part from the lack of 
information concerning the long-term side effects associated with 
usage.67  Information regarding side effects of short-term use, 
however, is more readily available.68  Those short-term effects 
include impairment to cognitive functions, drowsiness, and 
60. Id. at 893 (“In 2017, the National Academies found ‘substantial
evidence’ that marijuana (and its subcomponents) can also help alleviate 
chronic pain.”); Annie Bach Yen Nguyen, The Alternative to Opioids: 
Marijuana’s Ability to Manage Pain Caused by Injuries Sustained in the 
National Football League, 19 TEX. REV. ENT. & SPORTS L. 63, 72 (2019).
Marijuana comes from the cannabis plant which contains various natural 
compounds called cannabinoids.  Nguyen, supra at 72.  Two cannabinoids 
found in the cannabis plant are “delta-9-tetrahydrocannabinol (‘THC’) and 
cannabidiol (‘CBD’).”  Id.  While THC is known to have psychoactive effects on 
the user, CBD does not.  Id. 
61. Nguyen, supra note 60 at 73.
62. Id.
63. Jorge Manzanares et al., Role of the Cannabinoid System in Pain
Control and Therapeutic Implications for the Management of Acute and 
Chronic Pain Episodes, 4 CURRENT NEUROPHARMACOLOGY 239, 248 (2006). 
64. Hodge, supra note 54, at 893.
65. Id. at 897.
66. See id.
67. See Volkow et al., supra note 42, at 2222–23.
68. See Hodge, supra note 54, at 893.
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confusion.69  There is evidence that extended medical marijuana 
use may lead to various respiratory diseases or psychosis.70  
However, when compared with the long-term side effects of opioid 
use—which include bowel obstruction caused by chronic 
constipation, sleep-disordered breathing, increased risk of 
fractures, and risk of addiction—the long-term effects of marijuana 
use are much more palatable.71   
Requiring Rhode Island workers’ compensation insurers to 
reimburse employees for out-of-pocket costs associated with 
medical marijuana will save insurers money.  In addition, medical 
marijuana is a better alternative to other pain-management 
medications—it is less expensive, less addictive, and overall a 
potential solution to the opioid crisis, making it a viable substitute 
given public policy concerns.  Any argument that cost or health-
related effects inhibits reimbursement is without merit.  Not only 
is reimbursement more cost-effective for insurers, it is better for 
injured employees and, therefore, a better alternative overall. 
IV. ADDRESSING THE FEDERAL PROHIBITION
In 1970, the federal Controlled Substances Act (CSA) was 
introduced under the Nixon Administration as a way of 
streamlining all federal laws related to drug enforcement.72  The 
CSA classifies controlled substances into one of five schedules.73  
Schedule determinations are based on the drug’s “accepted medical 
uses, potential for abuse, and psychological and physical effects on 
the body.”74  Marijuana is currently classified as a Schedule I drug, 
69. Id. at 893–94; Ramsin Benyamin et al., Opioid Complications and Side
Effects, 11 PAIN PHYSICIANS S105, S105 (2008).  Although there are short-term 
side effects associated with marijuana use, those symptoms are more tolerable 
than the short-term side effects of opioid use, which include “sedation, 
dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and 
respiratory depression.”  Benyamin et al., supra at S105.  
70. Hodge, supra note 54, at 894.
71. AnGee Baldini et al., A Review of Potential Adverse Effects of Long-
Term Opioid Therapy: A Practitioner’s Guide, 14 PRIMARY CARE COMPANION 
FOR CNS DISORDERS (June 14, 2012). 
72. Fern L. Kletter, Annotation, Construction and Application of the
Controlled Substances Act, 21 U.S.C.A. §§ 801 et seq.—U.S. Supreme Court 
Cases 30 A.L.R Fed. 2d. 137, § 2 (2008).  
73. Id.
74. Id.
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meaning that under the CSA, marijuana has “a high potential for 
abuse,” “no current accepted medical use in treatment in the United 
States,” and is not safe to use under medical supervision.75  
Although marijuana is classified as a Schedule I drug under the 
CSA, there are several notable declassification movements, given 
the wealth of contrary scientific research and the abundance of 
states that have legalized marijuana for medical and recreational 
uses.76  The CSA defines several unlawful acts related to controlled 
substances that are punishable at various levels, depending on the 
schedule of the controlled substance at issue.77  Prohibited acts 
include “manufactur[ing], distribut[ing], or dispens[ing], or 
possess[ing] with the intent to manufacture, distribute, or dispense, 
a controlled substance.”78  Thus, in order to be prosecuted under 
the CSA, an individual would have to commit one of the above-
defined offenses. 
In 2013, James M. Cole, then-Deputy Attorney General at the 
United States Department of Justice, issued a memorandum (the 
Cole Memo) to all United States Attorneys on the subject of 
marijuana enforcement under the CSA.79  The Cole Memo 
reiterates the guidance articulated in the Department of Justice’s 
earlier Ogden memorandum that, going forward, due to its limited 
financial resources, the Department of Justice only would focus on 
75. 21 U.S.C. § 812(b)(1), (c)(I)(c)(10) (2018); contra Hodge, supra note 54,
at 893 (stating that medical marijuana is known as an effective treatment for 
various illnesses according to the National Academies, which in 2017 found 
there was substantial evidence that medical marijuana is effective in 
alleviating chronic pain, indicating that there is an accepted use in treatment 
in the United States and that it is safe to use under medical supervision (citing 
NAT’L ACADS. OF SCIS. ENG’G, & MED. THE HEALTH EFFECTS OF CANNABIS AND 
CANNABINOIDS: THE CURRENT STATE OF EVIDENCE AND RECOMMENDATIONS FOR
RESEARCH 87–90 (2017)). 
76. See, e.g., Strengthening the Tenth Amendment Through Entrusting
States Act, S. 3032, 115th Cong. (2018).  Senator Elizabeth Warren and 
Senator Cory Gardner introduced the STATES Act to expressly exempt 
cannabis use in legalized states from federal prosecution.  President Trump 
has expressed support of the bill. 
77. 21 U.S.C. § 841(a).
78. § 841(a)(1).  Punishable offenses also include “creat[ing], distribut[ing],
or dispens[ing], or possess[ing] with intent to distribute or dispense, a 
counterfeit substance.” § 841(a)(2). 
79. See Cole, supra note 31, at 217.
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eight areas of marijuana-related enforcement.80  Enforcement 
areas include: 
[1] Preventing the distribution of marijuana to minors; [2]
Preventing revenue from the sale of marijuana from going
to criminal enterprises, gangs, and cartels; [3] Preventing
the diversion of marijuana from states where it is legal
under state law in some form to other states; [4] Preventing
state-authorized marijuana activity from being used as a
cover or pretext for the trafficking of other illegal drugs or
other illegal activity; [5] Preventing violence and the use of
firearms in the cultivation and distribution of marijuana;
[6] Preventing drugged driving and the exacerbation of
other adverse public health consequences associated with
marijuana use; [7] Preventing the growing of marijuana on
public lands and the attendant public safety and
environmental dangers posed by marijuana production on
public lands; and [8] Preventing marijuana possession or
use on federal property.81
Outside these eight core areas, the Cole Memo stated that the 
Department of Justice will defer to state or local authorities, 
confirming that there is no federal intention to prosecute outside of 
the defined areas.82  Moreover, the Cole Memo afforded deference 
to state and local governments in states which have legalized 
marijuana in some form under comprehensive regulatory systems, 
as these systems effectively eliminate threats to the general public 
welfare that might arise from marijuana operations.83  
At the outset of the Trump Administration, then-Attorney 
General Jefferson B. Sessions III released a subsequent 
memorandum (the Sessions Memo) which stated that United States 
attorneys should continue to prosecute all marijuana-related 
offenses.84  However, several United States Attorney’s offices have 
80. Id.
81. Id. at 217–18.
82. See id.
83. Id. at 218–19.
84. Memorandum from Jefferson B. Sessions, III, Attorney Gen. on
Marijuana Enforcement to all U.S. Attorneys (Jan. 4, 2018), 
https://www.justice.gov/opa/press-release/file/1022196/download [https:// 
perma.cc/PFP6-X57S]. 
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responded with statements that they will continue to follow the 
guidance in the Cole Memo, meaning that they will not prosecute 
outside the eight areas of enforcement detailed therein, potentially 
because there is neither the funding nor the desire to prosecute 
outside of those areas.85  Furthermore, the Rohrabacher-
Blumenauer Amendment to the federal Omnibus Spending Bill, 
which became law in 2014, prohibits the Department of Justice 
from spending funds to interfere with the implementation of state 
medical marijuana laws.86 
A. There is No Credible Threat of Federal Prosecution Under the
Controlled Substances Act Because Reimbursing Employees for
Medical Marijuana is Not Prohibited Conduct.
Those opposed to requiring Rhode Island workers’ 
compensation insurers to reimburse employees for expenses related 
to medical marijuana point out that marijuana is still prohibited 
under the CSA,87 thus raising a possible threat of federal 
prosecution.  However, this argument lacks merit because such 
reimbursements do not fall within the scope of the CSA, which 
punishes enumerated crimes such as the manufacture, 
dispensation, possession, or distribution of marijuana.88  One New 
Jersey workers’ compensation court judge, in response to a similar 
argument, stated: “Certainly I don’t understand how [an insurance] 
carrier, who will never possess, never distribute, never intend to 
distribute these products, who will nearly [sic] sign a check into an 
attorney’s trust account is in any way complicit with the 
distribution of illicit narcotics.”89  Insurers who reimburse 
employees for medical marijuana would not be manufacturing 
marijuana, they would not be dispensing or distributing marijuana, 
nor would they even be in possession of marijuana.90  Further, 
insurers would only be issuing a reimbursement check, for a certain 
85. Lawrence O. Gostin et al., Opinion, Enforcing Federal Drug Laws in
States Where Medical Marijuana is Lawful, 319 JAMA 1435, 1436 (2018). 
86. Consolidated Appropriations Act, 2019, Pub. L. No. 116–6, § 537, 133
Stat. 13, 138. 
87. Lynch, supra note 1.
88. 21 U.S.C. § 841(a) (2018).
89. Transcript of Record at 11, McNeary v. Freehold Township, No. 2007–
10498, 2008–8094, 2014–10233 (N.J. Workers’ Comp. Ct. June 28, 2018). 
90. Id.
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amount, to the injured employee.  Insurers would have no 
involvement in the employee’s certification and registration in the 
medical marijuana program, as that comes under the responsibility 
of a medical practitioner.91  Because workers’ compensation 
insurers would be committing no unlawful act under the CSA, the 
argument that federal prosecution is a bar to reimbursement fails 
on its face. 
A dissenting opinion by Justice Joseph M. Jabar of the Maine 
Supreme Judicial Court in the case of Bourgoin v. Twin Rivers 
Paper Co. provides an example of the changing attitude towards the 
argument that federal prosecution is an obstacle to 
reimbursement.92  The dissent concludes that because the CSA only 
prohibits the manufacture, dispensation, possession, and 
distribution of marijuana, insurers do nothing wrong by 
reimbursing an employee for the associated costs of marijuana.93  
Hence, there is no conflict with the CSA because no prohibited 
conduct takes place.94  As described above, the insurer simply signs 
a check and does nothing else.  The dissent rejected the majority’s 
argument that although the insurer would not actually partake in 
prohibited conduct, it would be aiding and abetting the employee’s 
possession.95  The dissent found this argument unpersuasive 
because a prosecutor would never be able to prove that the insurer 
had the requisite mens rea to prove the offense of aiding and 
abetting.96   
Even if there was some violation for which insurers could be 
prosecuted under the CSA, the eight enforcement priorities detailed 
in the Cole Memo indicate that an attempted prosecution is highly 
unlikely.97  Although the Cole Memo is no longer authoritative on 
the subject, the fact remains that the Department of Justice is 
limited in the manner in which it may allocate funds for marijuana 
91. 21 R.I. GEN. LAWS § 21-28.6-3(30).
92. See Bourgoin v. Twin Rivers Paper Co., 187 A.3d 10, 24 (Me. 2018)
(Jabar, J., dissenting). 
93. Id.
94. Id.
95. Id. at 25.
96. Id.
97. See Cole, supra note 31, at 217–18.
518 ROGER WILLIAMS UNIVERSITY LAW REVIEW [Vol. 25:500 
enforcement;98 accordingly, some United States Attorneys have 
focused prosecution efforts on larger areas of concern, such as 
preventing distribution to minors, marijuana diversion, and 
revenue going to criminal enterprises, gangs, and cartels.99  In the 
Cole Memo, which many United States Attorneys still follow, 
reimbursement of costs to a qualified state medical marijuana 
program patient is not an identified enforcement area.100  
Moreover, reimbursement would only occur where an employee 
qualifies under the extensive requirements outlined in both the 
Slater Act and the Rhode Island Workers’ Compensation Act.  The 
reimbursement of costs associated with medical marijuana in the 
workers’ compensation context is the exact type of activity where 
the federal government, under the Cole Memo, was instructed to 
give deference to state authorities.101  Only under a comprehensive 
scheme of regulatory measures are injured employees even able to 
access medical marijuana.  Employee access to medical marijuana 
is further restricted based upon the quantities legally allowed 
under the Slater Act, essentially eliminating any potential for 
abuse.102  Thus, reimbursement for such state-sanctioned 
marijuana use is exactly the type of permissible activity alluded to 
in the Cole Memo.103 
B. Where States Have Affirmatively Required Workers’
Compensation Insurers to Reimburse the Expenses Associated with
Medical Marijuana, No Prosecutions have Resulted.
Several states have affirmatively required workers’ 
compensation insurers to reimburse employees for the costs of 
medical marijuana on the premise that the federal government has 
no basis for prosecution because insurers commit no crime in 
98. See Tom Angell, Congress Votes to Stop Feds from Enforcing




99. Gostin et al., supra note 85, at 1436; see also Cole, supra note 31, at
217–18. 
100. See Cole, supra note 31, at 217–18.
101. See id. at 218–19.
102. 21 R.I. GEN. LAWS § 21-28.6-12(g)(1); see also supra notes 43–49 and
accompanying text. 
103. See Cole, supra note 31, at 218–19.
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reimbursing employees.104  Currently, New Mexico has the most 
case law in the area and is widely-cited by those requiring 
affirmative reimbursement.105  Notable cases include Lewis v. 
American General Media, Maez v. Riley Industrial, and Vialpando 
v. Ben’s Automotive Services.106  In the above-mentioned cases, the
reasoning for affirmative reimbursement is two-fold.  In each case,
the workers’ compensation insurer was unable to identify a statute
that it would be forced to violate.107  Thus, because there is no
articulable statutory violation, there is no threat of federal
prosecution, essentially foreclosing any argument that
reimbursement would result in illegal conduct.108  Additionally, the
court in Vialpando relied on the Cole Memo.109  The Department of
Justice has consistently stressed eight areas of enforcement
regarding marijuana and, outside of these eight areas, the
Department defers to state and local authority.110  Given that the
reimbursement of medical marijuana in the workers’ compensation
context falls outside of the areas detailed in the Cole Memo, the
court concluded that an affirmative reimbursement requirement
would result in no federal prosecutions.111  The court also
highlighted that legislative intent regarding public policy was a
factor in its decision to affirmatively require reimbursement.112
104. States affirmatively requiring reimbursement include New Mexico,
New Jersey, Connecticut, New York, and Minnesota.  INS. INFO. INST., HAZE OF
CONFUSION: HOW EMPLOYERS AND INSURERS ARE AFFECTED BY A PATCHWORK OF
STATE MARIJUANA LAWS 12–13 (June 2019), https://www.iii.org/sites/ 
default/files/docs/pdf/marijuanaandemploy_wp_062019.pdf [https://perma.cc/ 
K4FH-UL49].   
105. H. Scott Curtis, Cannabis & Workers’ Compensation Law, MD. B.J.,
Nov. 2017, at 24, 27. 
106. Lewis v. Am. Gen. Media, 355 P.3d 850 (N.M. Ct. App. 2015); Maez v.
Riley Indus., 347 P.3d 732 (N.M. Ct. App. 2015); Vialpando v. Ben’s Auto. 
Servs., 331 P.3d 975 (N.M. Ct. App. 2014).  
107. See, e.g., Vialpando, 331 P.3d at 980.
108. See id. at 979.
109. Id. at 980.
110. Id.
111. See id. at 979–80.
112. Id. at 980 (“We also observe that New Mexico public policy is clear.
Our State Legislature passed the Lynn and Erin Compassionate Use Act ‘to 
allow the beneficial use of medical cannabis in a regulated system for 
alleviating symptoms caused by debilitating medical conditions and their 
medical treatments.’”). 
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Likewise, New Jersey has affirmatively required workers’ 
compensation insurers to reimburse employees for the costs of 
medical marijuana because there is no identifiable violation of 
federal law.113  In McNeary v. Freehold Township, the New Jersey 
workers’ compensation court required the insurer to reimburse the 
employee for two reasons.114  First, similar to the reasoning 
employed in the New Mexico cases, the court concluded there is no 
federal violation committed when reimbursing an employee for the 
costs of medical marijuana because the insurer takes no part in any 
conduct prohibited by the CSA.115  The court reasoned that a 
workers’ compensation insurer does not manufacture, dispense, 
distribute, or possess the marijuana at any point in the 
reimbursement process.116  The insurer merely signs a check and 
tenders it to the employee, thus there is no CSA violation.117  
Second, the court required the insurer to reimburse the employee 
under the New Jersey Workers’ Compensation Act because the 
employee had proven a medical need for the marijuana in 
conjunction with his work-related injury.118  Moreover, the court 
referenced public policy as a reason for reimbursement, noting that 
medical marijuana should be considered in light of the opioid 
crisis.119 
Delaware and Connecticut have also followed this trend by 
affirmatively requiring workers’ compensation insurers to 
reimburse employees for medical marijuana.120  Unlike New 
Mexico and New Jersey, which premise reimbursement on the lack 
of federal crime and prosecution, Delaware and Connecticut 
analyze reimbursement under the requirements of their applicable 
workers’ compensation acts.121  So long as the medical marijuana 
113. Transcript of Record at 12–13, McNeary v. Freehold Township, No.
2007–10498, 2008–8094, 2014–10233 (N.J. Workers’ Comp. Ct. June 28, 2018). 
114. Id. at 11.
115. Id. at 10–11.




120. Giles & Ransome v. Kalix, No. N17A-10-001 CEB, 2018 WL 4922911,
at *4 (Del. Super. Ct. Oct. 9, 2018); Petrini v. Marcus Dairy, Inc., No. 6021 
CRB-7-15-7 (Conn. Workers’ Comp. Comm’n Comp. Rev. Bd. Dec. 18, 2015). 
121. Giles & Ransome, 2018 WL 4922911, at *2–3; Petrini, No. 6021 CRB-
7-15-7.
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is medically necessary to rehabilitate the employee’s injury and the 
treatment is reasonable, reimbursement is required.122  The 
Connecticut review board also required patient compliance with 
Connecticut’s medical marijuana law for reimbursement.123  And, 
although Delaware does not expressly require patient compliance 
with state medical marijuana laws, it can be inferred that 
compliance with state law is also a prerequisite to 
reimbursement.124  The issue of the federal prohibition is neither 
argued nor mentioned by either decisionmaker in either case.125  
Because there is no inquiry into the federal prohibition in either 
case, one can reasonably infer that the Connecticut and Delaware 
workers’ compensation courts deemed it irrelevant to disposition of 
the matter. 
As of January 2020, there have been no federal prosecutions of 
any of the workers’ compensation insurers who have reimbursed 
employees for medical marijuana costs.126  The lack of federal 
prosecutions is due to the fact that there is no violation for which 
the federal government can charge a workers’ compensation 
insurer.127  Not only is there no violation of federal law, the 
reimbursement of medical marijuana in the workers’ compensation 
context falls outside of the Cole Memo enforcement priorities of the 
Department of Justice.128  Furthermore, federal funds may not be 
used to interfere with state medical marijuana laws which would 
include cost reimbursement to qualified patients in the workers’ 
compensation context.129  Not only is there no legal basis for 
prosecution, there are no means to prosecute.130  Given the above, 
122. Giles & Ransome, 2018 WL 4922911, at *2–3; Petrini, No. 6021 CRB-
7-15-7.
123. See Petrini, No. 6021 CRB-7-15-7.
124. See Giles & Ransome, 2018 WL 4922911, at *4.
125. See generally Giles & Ransome, 2018 WL 4922911; see generally
Petrini, No. 6021 CRB-7-15-7. 
126. An in-depth search was conducted on LexisNexis, Westlaw, and
Google.  No evidence of federal prosecutions was found.  Given the lack of 
evidence, one can conclude that there have been no prosecutions of workers’ 
compensation insurers under the Controlled Substances Act for reimbursing 
employees for the costs associated with medical marijuana. 
127. See 21 U.S.C. § 841(a) (2018).
128. Cole, supra note 31, at 217–18.
129. Angell, supra note 98.
130. Id.
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any argument that threat of federal prosecution is an obstacle to 
reimbursing employees for the costs associated with medical 
marijuana is wholly without merit. 
V. STATUTORY REFORM
Ultimately, the Slater Act should be amended to delete the 
carve out for workers’ compensation insurers.  Furthermore, the 
Rhode Island Workers’ Compensation Act should be amended to 
affirmatively require workers’ compensation insurers to reimburse 
employees for the associated costs of medical marijuana where it is 
necessary to cure, relieve, or rehabilitate their injuries.  Because 
the  cost of medical marijuana is less expensive than that of opioids 
and because medical marijuana may be a better alternative for 
injured employees, reimbursement is beneficial to both insurers 
and employees.  Insurers would save money by reimbursing injured 
employees for costs associated with medical marijuana because 
such reimbursement would reduce opioid-related claims which 
drive up costs.  With the availability of medical marijuana, 
employees would have an alternative to opioid prescriptions, 
therefore decreasing the risk of addiction.   
Not only should affirmative reimbursement be required, the 
Rhode Island Workers’ Compensation Act should be amended to 
clarify the requirements for reimbursement.  Reimbursement 
parameters should require the employee to fulfill the prerequisites 
to register as a qualifying patient under the Slater Act and the 
requirements of the Rhode Island Workers’ Compensation Act for 
reimbursement of medical costs.  By detailing a strict scheme for 
reimbursement, workers’ compensation insurers would be 
protected from unfounded claims and the compensation floodgates. 
These clarifying amendments would confirm compliance with the 
CSA and the Cole Memo’s federal guidance, ensuring ironclad 
insulation from threat of federal prosecution for insurers.  
CONCLUSION 
The Rhode Island Workers’ Compensation Court’s mission is 
“to provide reliable and reasonable benefits in a just and efficient 
manner, with compassion and respect, to all employees who suffer 
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a work-related injury.”131  Workers’ compensation insurers view 
medical marijuana reimbursement through a narrow lens;  that is, 
in a way that only takes into account their own interests.  Insurers 
often fail to recognize the practical effects that reimbursement for 
medical marijuana would have on injured employees.  The average 
workers’ compensation employee is an individual who has suffered 
an injury, usually not as a result of her own fault, who is out work 
receiving significantly less than her normal paycheck, and who 
ultimately wants to return to work fully healed, all while trying to 
find viable methods to do so.  Not only is medical marijuana 
reasonable and reliable, its reimbursement is beneficial to both 
workers’ compensation insurers and injured employees.  To deny an 
injured employee, who seeks a cost-effective and legal alternative 
to traditional pain management prescriptions, a chance to heal and 
return to work, goes against the overall mission of the Rhode Island 
Workers’ Compensation Court.  As such, Rhode Island should 
require workers’ compensation insurers to reimburse employees 
who have been injured on the job for out-of-pocket expenses 
associated with medical marijuana. 
131. Workers’ Compensation Court, RHODE ISLAND JUDICIARY, 
https://www.courts.ri.gov/Courts/workerscompensationcourt/Pages/default.as
px [https://perma.cc/75WV-EXBB] (last visited Apr. 11, 2020). 
